Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Taylor Momsen explains why she quit 'Gossip Girl': 'I really didn't want to be there' - 2Wedding trip Objections in the US
- 3Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
- 42024 Style: The It-Things You Want in Your Closet
- 5The most effective method to Promoter for Cutthroat Medical attendant Compensations in Your Medical services Office
- China's Normal Ponders: A Visual Excursion
- Pick Your Favored kind of soup
- New heart disease calculator predicts 30-year risk for young adults
- Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women
- College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- Incredible Travel Objections for Craftsmanship Darlings to Visit
- Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- Soldiers seize power in Guinea-Bissau and detain the president
- The Magnificence of Do-It-Yourself Skincare: Regular Recipes and Tips
